Alcon has been granted a patent for azabicyclo and diazepine derivatives that act as modulators of muscarinic receptors. These compounds are used in pharmaceutical compositions for treating ocular diseases. GlobalData’s report on Alcon gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Alcon Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Alcon, Prosthetic cardiac valves was a key innovation area identified from patents. Alcon's grant share as of January 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

Ocular disease treatment using muscarinic receptor modulators

Source: United States Patent and Trademark Office (USPTO). Credit: Alcon Inc

A recently granted patent (Publication Number: US11884666B2) discloses a compound or a pharmaceutically acceptable salt thereof, represented by formula (II). The patent further details a pharmaceutical composition comprising the mentioned compound or salt along with one or more pharmaceutically acceptable carriers. Additionally, the composition is specified to be ophthalmically compatible, containing a therapeutically effective amount of the compound or salt, ranging from 0.01 to 10.0 weight percent.

Moreover, the patent outlines a method for treating mammalian subjects with or at risk of ocular disorders by administering the compound or salt in an effective amount. The patent also covers a combination therapy involving the compound or salt along with one or more therapeutically active agents. The compositions mentioned in the patent can be either topical or ophthalmic, providing a versatile approach to treating ocular conditions effectively.

To know more about GlobalData’s detailed insights on Alcon, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.